WT1 and acute myeloid leukemia: In the post-Allo-SCT setting, Israyelyan et al. prospectively evaluated 82 patients with various myeloid malignancies (including 39 AML) and reported that, at a standard cut-off of 50 copies of WT1/104 ABL, the method used for MRD monitoring had a specificity of 100% (positive predictive value 100%) and a sensitivity of 75% in detecting relapse [48].